- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01304628
Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
December 15, 2014 updated by: Palatin Technologies, Inc
A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma
The objective of this study is to evaluate if single subcutaneous (SC) doses of PL-3994, administered to patients with asthma can achieve a clinically meaningful increase in pulmonary function (Forced Expiratory Volume in one second: FEV1) while maintaining an acceptable safety profile.
The study will characterize the bronchodilator effect, dose and safety of PL-3994 in a population of moderately severe, stable asthmatics following overnight withdrawal of beta-2 agonists.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Cranbury, New Jersey, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has provided written informed consent
- The subject is male or female >18 to 65 years of age
- Patient has a clinical history of asthma as defined by the National Asthma Education and Prevention Program.
- Documented bronchodilator response to albuterol as defined by the American Thoracic Society (> 200 mL and > 12% increase in FEV1 after bronchodilator inhalation)
- FEV1 post-bronchodilator of between 55% and 80% predicted.
- Currently taking 200-1000 mcg (fluticasone equivalent) of inhaled corticosteroids
- All inclusion criteria met within the past 12 months.
- If the subject or subject's partner is of child-bearing potential, a medically acceptable form of contraception will be used for three months prior to the screening visit (females only), for the duration of the study and for one month following the last dose of the study drug. Medically acceptable contraceptives include: (1) surgical sterilization, (2) FDA-approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide.
If the subject had a vasectomy greater than 6 months prior to the screen visit, this will also be acceptable.
Exclusion Criteria:
Current diagnosis, as per subject or investigator or screening assessment, of:
- unstable or uncontrolled disease in any organ system (including cardiovascular) on present therapy
- psychiatric disease requiring daily medication, including controlled or uncontrolled schizophrenia or any other uncontrolled psychiatric condition
- significant neurological disease
- current or history of any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior to screening
- acute or chronic disease requiring frequent changes in medications or changes in dosages of chronic therapy
- history of alcohol abuse within the past 5 years
- positive result for the alcohol and/or drug tests at screening or check-in
- positive for HIV, or Hep B&C at screening
- blood donation within 30 days of screening or plasma donation within 7 days of screening
- weight > 100 kg or < 50 kg
- clinically significant electrocardiogram (ECG) at screening
- any clinically significant (per the investigator) lab abnormalities
- any fever or other clinically significant physical exam abnormalities
- History of COPD or any other lung disease
- Greater than 10 packs per year smoking history and any cigarette smoking within the past 12 months
- Patients unable to withhold bronchodilator treatment for 12 hours prior to dosing
- Patients with hypoxia at screen or Check -in Visit 2, Day 1 or Visit 3, Day 7 (oxygen saturation measured by pulse oximetry [SpO2] < 90%)
- Tachycardia (heart rate > 100 beats/min) at screening
- Currently being treated for Hypertension or taking any other medications that affect blood pressure significantly.
- Currently taking any medications that inhibit PDE activity or which affect the cyclic guanisine mono-phosphate (cGMP) pathway (e.g. theophylline). These medications will be prohibited during the study and for at least 5 half- lives prior to Check-in Visit 2, Day 1 or Visit 3, Day 7 so that cGMP measurements will not be affected.
- Hypotension (systolic blood pressure < 110 mmHg) at Screening or Check-in Visit 2, Day 1 or Visit 3, Day 7
- Chronic kidney disease defined as estimated glomerular filtration rate (eGFR) <50 mL/m2.
- Diagnosis of heart failure or history of hospitalization for congestive heart failure.
- History of coronary artery disease defined as prior myocardial infarction, prior revascularization procedure, or >50% coronary artery obstruction by angiography.
- Prior history of stroke or transient ischemic attack.
- Female patients of childbearing potential who are nursing or have a positive pregnancy test at Screening or Check -in Visit 2, Day 1 or Visit 3, Day 7
- Any major disability or disease with expected survival less than 6 months
- Administration of any investigational drug or implantation of investigational device, or participation in another trial, within 30 days of screening.
- Inability to perform acceptable, quality serial spirometry
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
subcutaneous PL-3994, single dose, 4 escalating dose groups
|
Experimental: PL-3994 (4 escalating doses)
|
subcutaneous PL-3994, single dose, 4 escalating dose groups
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Forced Expiratory Volume in one second (FEV1)
Time Frame: Throughout 12 hours post dosing
|
Serial spirometry measures, including FEV1, assessed at specified time periods over 12 hours post dose.
|
Throughout 12 hours post dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Forced Vital Capacity (FVC)
Time Frame: Throughout 12 hours post dosing
|
Serial spirometry measures, including FVC, assessed at specified time periods over 12 hours post dose.
|
Throughout 12 hours post dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
February 22, 2011
First Submitted That Met QC Criteria
February 24, 2011
First Posted (Estimate)
February 25, 2011
Study Record Updates
Last Update Posted (Estimate)
December 16, 2014
Last Update Submitted That Met QC Criteria
December 15, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PL-3994-501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on PL-3994
-
Palatin Technologies, IncRecruitingHeart Failure With Preserved Ejection FractionUnited States
-
The Hong Kong Polytechnic UniversityThe University of Hong Kong; University of Magdeburg; University of WaterlooRecruiting
-
Human Stem Cell Institute, RussiaRyazan State Medical University; Vidnoe District HospitalCompletedUlcers Related to Diabetic Foot SyndromeRussian Federation
-
Karolinska University HospitalSwedish Foundation for Strategic ResearchRecruitingDysphonia | Hoarseness | Aphonia | Vocal Fold; ScarSweden
-
University of IcelandCompleted
-
Protelight Pharmaceuticals Australia PTY LTDRecruitingBacterial Vaginosis | Colpomycosis | Mixede VaginitisAustralia
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Pepperdine UniversityRecruitingHigh Nitrate Dose | Moderate Nitrate Dose | Low Nitrate Dose | Nitrate-depleted DoseUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Not yet recruiting